Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2025-07-16 00:00:00 ET · period of report 2025-07-15 · accession 0001140361-25-026099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-07-16 | 2025-07-15 | ADMA | Grossman Adam S | Pres, CEO, Dir | S - Sale+OE | $18.66 | -21.0K | 2.04M | -1% | -$391.9K |
| DT | 2025-07-16 | 2025-07-15 | ADMA | Grossman Adam S | Pres, CEO, Dir | M - OptEx | $5.40 | +15.0K | 2.06M | +0.7% | +$81.0K |
| DT | 2025-07-16 | 2025-07-15 | ADMA | Grossman Adam S | Pres, CEO, Dir | M - OptEx | $0.00 | -15.0K | 796.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-15 | S | D | 6,000 | $18.66 | 2,037,850 | D | — | — | (F1) Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. (F2) The price reported in Column 4 is the price at which the shares were sold. (F5) (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,005,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. (F4) (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (F3) Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; |
| 2 | Common | Common Stock | 2025-07-15 | S | D | 15,000 | $18.66 | 2,043,850 | D | — | — | (F1) Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. (F2) The price reported in Column 4 is the price at which the shares were sold. |
| 3 | Common | Common Stock | 2025-07-15 | M | A | 15,000 | $5.40 | 2,058,850 | D | — | — | (F1) Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. |
| 4 | Derivative | Stock Option (right to buy) | 2025-07-15 | M | D | 15,000 | $0.00 | 795,950 | D | $5.40 · — to 2034-02-26 | 15,000 Common Stock | (F1) Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. (F8) The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028. |